Skip to main content
Clinical Trials/NCT05036252
NCT05036252
Active, not recruiting
Not Applicable

A Pilot Study of Cardiopulmonary Exercise Testing in Patients With Left Ventricular Systolic Dysfunction Receiving HER2-Targeted Therapy

Memorial Sloan Kettering Cancer Center1 site in 1 country23 target enrollmentAugust 27, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Memorial Sloan Kettering Cancer Center
Enrollment
23
Locations
1
Primary Endpoint
Baseline VO2peak in participants with HER2-positive breast cancer
Status
Active, not recruiting
Last Updated
7 months ago

Overview

Brief Summary

The purpose of this study is to find out how much oxygen is used during a cardiopulmonary exercise test (CPET) in women who have mild cardiotoxicity after standard treatment for HER2-positive breast cancer, and to see whether the results of this test can be used to predict how well participants' heart and lungs will work if they continue to receive this kind of treatment.

Registry
clinicaltrials.gov
Start Date
August 27, 2021
End Date
August 27, 2026
Last Updated
7 months ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years
  • Diagnosed with a HER2-positive solid tumor (stage I-IV)
  • Left ventricular dysfunction prior to the start of HER2-targeted therapy, defined by a LVEF \< 53% (or lower limit of normal), or diagnosed with mild cardiotoxicity associated with HER2-targeted therapy, defined by an absolute decrease in LVEF ≥ 10% from pre-treatment to \< 53%
  • Planning to undergo treatment with HER2-targeted therapy (e.g. trastuzumab, pertuzumab, or ado-trastuzumab) for a minimum of 3 months (i.e. 4 cycles administered every 3 weeks).
  • Willing and able to comply with the requirements of the protocol

Exclusion Criteria

  • Symptomatic heart failure (New York Heart Association Class III or IV)
  • Subjects must not have any of the following absolute contraindications to cardiopulmonary exercise testing:
  • Acute myocardial infarction (within 30 days of any planned study procedures),
  • Unstable angina
  • Uncontrolled arrhythmias causing symptoms or hemodynamic compromise,
  • Symptomatic severe aortic stenosis
  • Recurrent syncope
  • Active endocarditis
  • Acute myocarditis or pericarditis
  • Acute pulmonary embolus or pulmonary infarction (within 3 months of any planned study procedures)

Outcomes

Primary Outcomes

Baseline VO2peak in participants with HER2-positive breast cancer

Time Frame: At baseline

The primary purpose is to evaluate baseline VO2peak in patients with HER2-positive solid tumors and left ventricular systolic dysfunction

Study Sites (1)

Loading locations...

Similar Trials